Active, not recruitingPhase 2NCT03603795
Study Impact on Outcome of Eltrombopag in Elderly Patients with Acute Myeloid Leukemia Receiving Induction Chemotherapy
Studying Acute myeloid leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- French Innovative Leukemia Organisation
- Principal Investigator
- Arnaud PIGNEUX, MD PDFrench Innovative Leukemia Organization (FILO)
- Intervention
- Eltrombopag(drug)
- Enrollment
- 110 enrolled
- Eligibility
- 60 years · All sexes
- Timeline
- 2018 – 2026
Study locations (15)
- CHU ANGERS - Maladies du sang, Angers, France
- CH de la Côte Basque - Hématologie, Bayonne, France
- CHU Estaing, Clermont-Ferrand, France
- CHU Grenoble - Hématologie Clinique, Grenoble, France
- Institut Paoli-Calmettes - Hématologie 2, Marseille, France
- Hôpital Saint-Eloi - Hématologie Clinique, Montpellier, France
- HOPITAL E. MULLER - Hématologie, Mulhouse, France
- CHU HOTEL DIEU - Hématologie Clinique, Nantes, France
- CHU Caremeau, Nîmes, France
- CHU La Milétrie - Hématologie Clinique, Poitiers, France
- CHU Pontchaillou, Rennes, France
- CHU Hautepierre - Hématologie, Strasbourg, France
- Institut Universitaire du Cancer de Toulouse Oncopole - Service d'Hématologie, Toulouse, France
- Sponsor FILO, Tours, France
- CHU de Brabois, Vandœuvre-lès-Nancy, France
Collaborators
Novartis Pharmaceuticals
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03603795 on ClinicalTrials.govOther trials for Acute myeloid leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07493538MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological DiseasesMasonic Cancer Center, University of Minnesota
- RECRUITINGPHASE2NCT07392242A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid LeukemiaMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE3NCT07075016Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive ChemotherapyStichting Hemato-Oncologie voor Volwassenen Nederland
- RECRUITINGPHASE1NCT06649227Study Investigating the Safety of CD19 CAR-T Cells in Relapsed/Refractory AML Expressing CD19University Hospital, Lille
- RECRUITINGNANCT07237230Clinical Study to Evaluate the Safety and Efficacy of γδ T Cells for the Prevention of Relapse After Allogeneic Transplantation in Patients With High-risk Acute Myeloid LeukemiaDonghua Zhang
- RECRUITINGPHASE1, PHASE2NCT06969430A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)Debiopharm International SA
- RECRUITINGNCT06899581Gut Health in Children With CancerGreat Ormond Street Hospital for Children NHS Foundation Trust
- RECRUITINGPHASE2NCT06783790Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCTInstitute of Hematology & Blood Diseases Hospital, China